VivoSeq
Oncology

Papilloma

116

Pipeline Programs↗

34

Active Trials↗

39

Companies Involved↗

Papilloma is a highly competitive landscape with 116 programs across 39 companies. The most active players are Antiva Biosciences, Repertoire Immune Medicines, Avyxa. 10 therapies are approved with 26 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

73/100

Pipeline Velocity

22/100

Mech. Concentration

8/100

Completion Rate

86/100

Attrition Rate

10/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

A

Antiva Biosciences

1 program

Phase 1R

Repertoire Immune Medicines

1 program

Phase 1A

Avyxa

1 program

Phase 1M

Meitheal

1 program

Phase 1AstraZeneca logo

AstraZeneca

4 programs

Phase 2E

Eastern Cooperative Oncology Group

2 programs

Phase 2

Pipeline

Programs by Phase

Preclinical9

Ribavirin

Conrado Roberto Hoffmann Filho

TNF-Alpha Inhibitors

Medical University of Vienna

Alternative/no Medication

Medical University of Vienna

Gardasil Vaccine

Johns Hopkins University

HPV-16/18 Vaccine

Shanghai Zerun Biotechnology Co.,Ltd

Phase 119

Carboplatin

Avyxa

Melphalan

Apotex Inc.

Topotecan

Meitheal

Avastin

Roche

Immunotherapy

Bristol-Myers Squibb

Phase 252

Pembrolizumab

Merck & Co.

Nivolumab

Bristol-Myers Squibb

Atezolizumab

Roche

Cisplatin

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Pemetrexed

Eagle Vision Pharmaceutical Corp.

Phase 326

Nonavalent HPV Vaccine

Xiamen University

Engerix-B

GSK

Boostrix

GSK

Gardasil9

Merck & Co.

Gardasil

Merck & Co.

Approved10

Celecoxib

Philadelphia Eye Associates

Cidofovir

Gilead

Vaccine

Pfizer

Human Papillomavirus Vaccination (gardasil)

Tuen Mun Hospital

Menveo/menactra

Massachusetts General Hospital

Analysis

Modality Breakdown

103programs
Small molecule5250%
Vaccine3635%
Monoclonal antibody1010%
Cell therapy33%
Protein / enzyme22%

Modality classified for 100% of 151 pipeline programs.

Analysis

Trial Status

175

clinical trials

Completed104 · 59%
Unknown status20 · 11%
Active, not recruiting18 · 10%
Recruiting12 · 7%
Terminated11 · 6%
Withdrawn6 · 3%
Other4 · 2%

Clinical Trials

Trial Activity

175 trials

Characteristics of Human Papillomavirus (HPV) Infections and HPV Vaccine Attitudes Among Slovenian Women After the Introduction of HPV Vaccination
Recruiting·UUniversity Medical Centre Ljubljana·N/A·NCT06995157·500 enrolled
SCG142 TCR-T Cells for Human Papillomavirus-Associated Carcinomas
Recruiting·TThe Affiliated Hospital of Qingdao University·Phase 1·NCT06544720·18 enrolled
A Phase III Clinical Trial of a 11-valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 9-45 Years
Recruiting·NNational Vaccine and Serum Institute, China·Phase 3·NCT05262010·13,500 enrolled
Toripalimab in Combination With Standard Treatment for Human Papillomavirus (HPV) Positive Throat Cancer
Recruiting·UUniversity of Chicago·Phase 2·NCT07290621·30 enrolled
Vaccination Against Human Papillomavirus (HPV) After Allogeneic Stem Cell Transplantation
Recruiting·—·Phase 2·NCT06793410·100 enrolled
Multiple Human Papillomavirus Infections in the Development of CIN
Recruiting·FFondazione IRCCS Policlinico San Matteo di Pavia·N/A·NCT06862102·152 enrolled
A Study to Assess the Reduction of Human Papillomavirus (HPV) Viral Infectivity and Transmission in HPV-Positive Women After Vaccination With 9vHPV (RIFT-HPV)
Recruiting·MMiquel Angel Pavon Ribas·Phase 4·NCT05334706·69 enrolled
E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers
Recruiting·—·Phase 2·NCT05686226·20 enrolled
Immunobridging Study of 9-valent Human Papillomavirus Recombinant Vaccine in Chinese Females Aged 9 to 19 Years
Recruiting·SShanghai Bovax Biotechnology Co., Ltd.·Phase 3·NCT04895020·1,200 enrolled
Therapeutic Vaccine in Patients With Human Papillomavirus HPV-positive Oropharyngeal Cancer
Recruiting·GGustave Roussy, Cancer Campus, Grand Paris·Phase 1/2·NCT06007092·24 enrolled
A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1
Recruiting·BioNTech logoBioNTech·Phase 2/3·NCT04534205·350 enrolled
Human Papillomavirus (HPV) Vaccination vs. Placebo for the Treatment of Refractory Cutaneous Warts
Recruiting·WWestern Institute for Veterans Research·Phase 2/3·NCT05625633·120 enrolled
Long-term Follow-up of Bivalent Human Papillomavirus (HPV) Vaccine Study in Women
Active, not recruiting·SShanghai Zerun Biotechnology Co.,Ltd·N/A·NCT06776055·5,372 enrolled
Immunogenicity of the 9-Valent Human Papillomavirus Recombinant Vaccine in People With Idiopathic CD4 T Cell Lymphocytopenia
Active, not recruiting·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT03519464·54 enrolled
Phase IIIb Clinical Trial of Quadrivalent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) for Age/Immunization Schedule Bridging
Active, not recruiting·NNational Vaccine and Serum Institute, China·Phase 3·NCT06632912·1,800 enrolled
Page 1 of 12

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)